Br[CH2:2][CH2:3][CH2:4][C:5](Cl)=[O:6].[NH2:8][C:9]1[CH:10]=[C:11]([CH3:33])[C:12]([N:15]2[CH2:32][CH2:31][C:18]3([C:22](=[O:23])[N:21]([C@H:24]4[CH2:29][CH2:28][C@@H:27]([OH:30])[CH2:26][CH2:25]4)[CH2:20][CH2:19]3)[CH2:17][CH2:16]2)=[N:13][CH:14]=1.CC(C)([O-])C.[K+]>CN(C)C1C=CN=CC=1.ClCCl.O1CCCC1>[OH:30][C@@H:27]1[CH2:26][CH2:25][C@H:24]([N:21]2[CH2:20][CH2:19][C:18]3([CH2:31][CH2:32][N:15]([C:12]4[C:11]([CH3:33])=[CH:10][C:9]([N:8]5[CH2:2][CH2:3][CH2:4][C:5]5=[O:6])=[CH:14][N:13]=4)[CH2:16][CH2:17]3)[C:22]2=[O:23])[CH2:29][CH2:28]14-Bromobutanoyl chloride (13.0 μL) was added to a mixture of 8-(5-amino-3-methylpyridin-2-yl)-2-(cis-4-hydroxycyclohexyl)-2,8-diazaspiro[4.5]decan-1-one (18.0 mg) and 4-dimethylaminopyridine (14.5 mg) in dichloromethane (1.0 mL). The mixture was stirred for 3 h. Then potassium tert-butoxide in tetrahydrofuran (1.0 M, 0.20 mL) was added. The mixture was stirred for an additional hour. The solvent was evaporated. The residue was dissolved in methanol (1.8 mL), and purified by prep.-HPLC under basic condition to afford 2-(cis-4-hydroxycyclohexyl)-8-[3-methyl-5-(2-oxopyrrolidin-1-yl)pyridin-2-yl]-2,8-diazaspiro[4.5]decan-1-one. LCMS: (M+H)+=427.20.